menu
    • menu
    [{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2||Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia||NF-?B\/NOS2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Amino Acid","year":"2019","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"Ammonia||NF-?B\/NOS2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yaqrit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2","graph1":"Neurology","graph2":"Phase II","graph3":"Yaqrit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yaqrit \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yaqrit \/ Undisclosed"},{"orgOrder":0,"company":"Ocera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Amino Acid","year":"2013","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2","graph1":"Neurology","graph2":"Phase II","graph3":"Ocera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ocera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"William Lee","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"IRELAND","productType":"Amino Acid","year":"2012","type":"Inapplicable","leadProduct":"Ornithine Phenylacetate","moa":"NF-?B\/NOS2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mallinckrodt Pharmaceuticals \/ William Lee","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ William Lee"}]

    Find Clinical Drug Pipeline Developments & Deals for Ornithine Phenylacetate

    Menu

    Ornithine Phenylacetate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yaqrit

                            United Kingdom arrow
                            Aquaexpo
                            Not Confirmed

                            Yaqrit

                            United Kingdom arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Yaqrit Prepares Phase 3 for Ammonia Scavenger in Hepatic Encephalopathy

                            Details : An ammonia scavenger, L-ornithine phenylacetate (OPA), is being evaluated for treatment of patients suffering from acute hepatic encephalopathy.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            February 11, 2025

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Aquaexpo
                            Not Confirmed

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function

                            Details : MNK-6105 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatic Encephalopathy.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            October 16, 2019

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ocera Therapeutics

                            Country arrow
                            Aquaexpo
                            Not Confirmed

                            Ocera Therapeutics

                            Country arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OCR002-SP103 - Oral Immediate Release Study

                            Details : OCR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            February 20, 2019

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ocera Therapeutics

                            Country arrow
                            Aquaexpo
                            Not Confirmed

                            Ocera Therapeutics

                            Country arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalop...

                            Details : Ornithine Phenylacetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatic Encephalopathy.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            October 21, 2013

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ocera Therapeutics

                            Country arrow
                            Aquaexpo
                            Not Confirmed

                            Ocera Therapeutics

                            Country arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emergency Use of OCR-002 in Acute Liver Failure (ALF)

                            Details : OCR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Liver Failure, Acute.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            July 06, 2012

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Aquaexpo
                            Not Confirmed

                            Mallinckrodt Pharmaceuticals

                            Ireland arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : William Lee

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

                            Details : Ornithine Phenylacetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Failure, Acute.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            March 08, 2012

                            Lead Product(s) : Ornithine Phenylacetate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : William Lee

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth